The nuclear medicine radioisotopes global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Nuclear Medicine Radioisotopes Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size -
The
nuclear medicine radioisotopes market size has grown strongly in recent
years. It will grow from $7.57 billion in 2023 to $8.21 billion in 2024
at a compound annual growth rate (CAGR) of 8.4%. The growth in the
historic period can be attributed to discovery of radioactivity,
emergence of nuclear medicine, therapeutic applications, clinical
research, and patient demand.
The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $11.44 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing healthcare spending, expansion of healthcare infrastructure, growing awareness of environmental sustainability, education campaigns and awareness programs and growth in medical tourism. Major trends in the forecast period include development of new radioisotopes, production and supply chain innovations, microfluidics and lab-on-a-chip technology, artificial intelligence in radiopharmaceutical development and nanotechnology.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/nuclear-medicine-radioisotopes-global-market-report
Scope Of Nuclear Medicine Radioisotopes Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Nuclear Medicine Radioisotopes Market Overview
Market Drivers -
The
rising cases of cardiovascular diseases are expected to propel the
growth of the nuclear medicine radioisotope market going forward.
Cardiovascular diseases refer to a group of diseases that affect the
heart and blood vessels. The rising cases of cardiovascular diseases are
due to sedentary lifestyles, poor dietary habits, increasing rates of
obesity, and aging populations. The nuclear medicine radioisotopes are
invaluable in diagnosing, evaluating, and managing cardiovascular
diseases with detailed insights into cardiac function, perfusion, and
tissue viability, which are essential for accurate diagnosis and
effective treatment planning. For instance, in May 2022, according to
the Centers for Disease Control and Prevention, a US-based governmental
organization, the prevalence of coronary heart disease among adults aged
18 and over stood at 4.6% in 2020, experiencing a slight uptick to 4.9%
in 2021. Therefore, the rising cases of cardiovascular diseases are
driving the growth of the nuclear medicine radioisotope market.
Market Trends -
Major
companies operating in the nuclear medicine radioisotopes market are
focusing on developing innovative products, such as the compact
low-energy cyclotron, to improve the production and availability of
radioisotopes, ensuring more efficient and accessible diagnostic and
therapeutic options. A compact, low-energy cyclone is a small particle
accelerator used to create radioisotopes for medical imaging and
treatments in nuclear medicine. For instance, in January 2022, IBA, a
Belgium-based provider of radiopharmaceutical production solutions,
launched Cyclone Key, a new accelerator providing increased access to
diagnostic solutions and enabling in-house production of
radiopharmaceuticals. This innovative solution offers unique features
such as a compact and efficient design, fully automated operation,
multiple isotope production capabilities, ease of installation and
operation, water cooling, self-shielding, and high performance, making
it versatile and reliable.
The nuclear medicine radioisotopes market covered in this report is segmented –
1)
By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine
(I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131),
Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Actinium-225
(Ac-225), Other Types
2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
Get an inside scoop of the nuclear medicine radioisotopes market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16132&type=smp
Regional Insights -
North
America was the largest region in the nuclear medicine radioisotopes
market in 2023. Asia-Pacific is expected to be the fastest-growing
region in the forecast period. The regions covered in the nuclear
medicine radioisotopes market report are Asia-Pacific, Western Europe,
Eastern Europe, North America, South America, Middle East, Africa.
Key Companies -
Major
companies operating in the nuclear medicine radioisotopes market are
Cardinal Health Inc., Bayer Aktiengesellschaft, Siemens Healthineers AG,
GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt
Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium
Pharma, Australian Nuclear Science and Technology Organisation (ANSTO)
Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes,
NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage
Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear
Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix
Inc., Positron Corporation
Table of Contents
1. Executive Summary
2. Nuclear Medicine Radioisotopes Market Report Structure
3. Nuclear Medicine Radioisotopes Market Trends And Strategies
4. Nuclear Medicine Radioisotopes Market – Macro Economic Scenario
5. Nuclear Medicine Radioisotopes Market Size And Growth
…..
27. Nuclear Medicine Radioisotopes Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
No comments:
Post a Comment